title: [Effect of Recombinant Super-compound Interferon (rSIFN-co) on Proliferation and Apoptosis of Human Pulmonary Adenocarcinoma Cell A549].
abstract: OBJECTIVE
  To investigate the effect of recombinant super-compound interferon (rSIFN-co) on the proliferation and apoptosis of pulmonary adenocarcinoma cell line A549.
  
  
  METHODS
  Screening tests were conducted to determine the concentrations of rSIFN-co that have a significant impact on A549 and the optimal concentration and duration for the test of rSIFN-co combined with Cisplatin. A549 cells were treated with rSIFN-co, Infergen, rSIFN- co+ Cisplatin, Infergen + Cisplatin, and Cisplatin, respectively, and compared with those cultured in normal medium. The viable A549 cells from Day 1 to Day 7 were detected by MTT assay. Cell apoptosis was detected by flow cytometry (FCM). Apoptosis-associated proteins, Fas and Bcl-2 were detected by immunofluoroscence at 48 h.
  
  
  RESULTS
  Effective concentrations of rSIFN-co ranged from 1 to 64 µg/mL, and a minimal of 2 µg/mL Cisplatin was needed. The optimal test condition was set at 5 µg/mL rSIFN-co combined with 2 µg/mL Cisplatin for a duration of 48 h. rSIFN-co demonstrated a stronger inhibiting effect on cell proliferation than Infergen. The inhibiting efficiency of rSIFN-co+Cisplatin was also stronger than that of Infergen+Cisplatin. Apoptosis of A549 cells induced by rSIFN-co was also more significant than that of Infergen (P = 0.000). Cells treated with rSIFN- co+ Cisplatin has a higher apoptosis rate than those treated with rSIFN-co (P = 0.004) or Cisplatin (P = 0.023). rSIFN-co increased the expression of Fas and decreased the expression of Bcl-2. Cells treated with rSIFN-co showed lower fluoroscence intensity of Bcl-2 than those treated with Infergen (P < 0.05).
  
  
  CONCLUSIONS
  rSIFN-co inhibits the proliferation of A549 and its effect is stronger than that of Infergen. Cisplatin can further enhance the inhibiting effect of rSIFN-co. The inhibiting efficiency may be associated with the expression of apoptosis-related genes.
authors.forename: Qi-wei
authors.initials: QW
authors.lastname: Kan
authors.forename: Lun-xu
authors.initials: LX
authors.lastname: Liu
authors.forename: Guang-wen
authors.initials: GW
authors.lastname: Wei
authors.forename: Qiang
authors.initials: Q
authors.lastname: Pu
authors.forename: Xue-peng
authors.initials: XP
authors.lastname: Zhuge
authors.forename: Lin
authors.initials: L
authors.lastname: Ma
authors.forename: Jun-liang
authors.initials: JL
authors.lastname: Ma
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D045744:Cell Line, Tumor / Q000187:drug effects; D049109:Cell Proliferation; D002945:Cisplatin / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology; D007372:Interferons / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000473:pathology; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; C050739:interferon alfacon-1; D007372:Interferons; D002945:Cisplatin